Protagonist Therapeutics, Inc.

Equities

PTGX

US74366E1029

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 10:58:56 2024-07-25 EDT 5-day change 1st Jan Change
42.14 USD +0.58% Intraday chart for Protagonist Therapeutics, Inc. +18.29% +84.21%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
JPMorgan Adjusts Price Target on Protagonist Therapeutics to $48 From $39, Maintains Overweight Rating MT
BTIG Raises Price Target on Protagonist Therapeutics to $51 From $41, Maintains Buy Rating MT
Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) added to S&P 1000 CI
Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) added to S&P 600 Health Care CI
Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) added to S&P Composite 1500 CI
Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) added to S&P 600 CI
Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) dropped from Russell 3000 Value Index CI
Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) dropped from Russell 2500 Value Index CI
Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) dropped from Russell Small Cap Comp Value Index CI
Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) dropped from Russell 2000 Value Index CI
Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) dropped from Russell 3000E Value Index CI
Protagonist Therapeutics to Join S&P SmallCap 600 MT
Protagonist Therapeutics, Inc. Reports Updated Long Term Results from Rusfertide Phase 2 REVIVE Study at the EHA2024 Congress Showowing Durable Hematocrit Control CI
Protagonist Therapeutics Insider Sold Shares Worth $1,231,650, According to a Recent SEC Filing MT
Protagonist Therapeutics Insider Sold Shares Worth $280,000, According to a Recent SEC Filing MT
Protagonist Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Protagonist Therapeutics Insider Sold Shares Worth $707,750, According to a Recent SEC Filing MT
Protagonist Therapeutics, Inc. Provides Update on Verify Patient Enrollment and Timing of Top-Line Data CI
Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda CI
Protagonist Therapeutics' Potential Plaque Psoriasis Drug Shows High Skin Clearance Rates in Phase 2B Study MT
Protagonist Therapeutics, Inc. Announces Late-Breaking Presentation At the American Academy of Dermatology 2024 Annual Meeting with Positive Results from the Phase 2B Frontier 2 Long-Term Extension Study Evaluating JNJ-2113, the First and Only Investigational Targeted Oral Peptide Designed to Block the IL-23 Receptor, for Adult Patients with Moderate-To-Severe Plaque Psoriasis CI
Protagonist Therapeutics Insider Sold Shares Worth $948,600, According to a Recent SEC Filing MT
Protagonist Therapeutics Insider Sold Shares Worth $406,637, According to a Recent SEC Filing MT
Protagonist Therapeutics Insider Sold Shares Worth $764,365, According to a Recent SEC Filing MT
JPMorgan Adjusts Price Target on Protagonist Therapeutics to $37 From $34, Maintains Overweight Rating MT
Chart Protagonist Therapeutics, Inc.
More charts
Logo Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc. is a biopharmaceutical company. The Company uses its peptide-based chemical entities rusfertide and JNJ-2113 in different stages of development, all derived from its proprietary discovery technology platform. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its lead clinical asset, rusfertide (PTG-300), is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. The Company’s Interleukin-23 receptor (IL-23R) antagonist compound JNJ-2113 is an orally delivered investigational drug that is designed to block biological pathways targeted by marketed injectable antibody drugs. Its PN-943 is a wholly owned investigational orally delivered gut-restricted alpha 4 beta 7 (α4β7) specific integrin antagonist for inflammatory bowel disease (IBD).
Employees
124
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
41.89USD
Average target price
45.50USD
Spread / Average Target
+8.62%
Consensus
  1. Stock Market
  2. Equities
  3. PTGX Stock
  4. News Protagonist Therapeutics, Inc.
  5. JPMorgan Adjusts Price Target on Protagonist Therapeutics to $37 From $34, Maintains Overweight Rating